Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 11:11:562363.
doi: 10.3389/fphar.2020.562363. eCollection 2020.

Efficacy and Safety of Artemisinin-Piperaquine for the Treatment of Uncomplicated Malaria: A Systematic Review

Qi Wang  1 , Yuanyuan Zou  1 , Ziyi Pan  1 , Hongying Zhang  1 , Changsheng Deng  1 , Yueming Yuan  1   2 , Jiawen Guo  1   2 , Yexiao Tang  1 , Nadia Julie  1 , Wanting Wu  1 , Guoming Li  1 , Mingqiang Li  1 , Ruixiang Tan  1 , Xinan Huang  1 , Wenfeng Guo  1 , Changqing Li  1 , Qin Xu  1 , Jianping Song  1
Affiliations

Efficacy and Safety of Artemisinin-Piperaquine for the Treatment of Uncomplicated Malaria: A Systematic Review

Qi Wang et al. Front Pharmacol. .

Abstract

Objective: The World Health Organization recommends artemisinin-based combination therapies (ACTs) for the treatment of uncomplicated malaria to improve the therapeutic efficacy and limit the choice of drug-resistant parasites. This systematic review and meta-analysis aimed to evaluate the comparative efficacy and safety of artemisinin-piperaquine (AP) in the treatment of uncomplicated malaria relative to other commonly used ACTs.

Methods: As per the PRISMA guidelines, the EMBASE, MEDLINE, the Google Scholar Library, and Cochrane library databases were systematically searched from inception until July 2020 with the following terms: "artemisinin-piperaquine" or "AP." Only randomized controlled trials (RCTs) were included. The competing interventions included dihydroartemisinin-piperaquine (DHA-PPQ), artemether-lumefantrine (AL, Coartem), artesunate-melfloquine (ASAM) and artesunate-amodiaquine (ASAQ, Artekin). Single-arm clinical trial on AP was also assessed. The reported outcomes, including the overall response, cure rate, fever and parasite clearance time, hematology, biochemistry, electrocardiogram (ECG), adverse events, recurrence rate, and sensitivity analyses, were systematically investigated. All data were analyzed using the Review Manager 5.3.

Results: A total of seven studies were reviewed, including five RCTs and two single-arm studies. A pooled analysis of 5 RCTs (n = 772) revealed a comparable efficacy on polymerase chain reaction (PCR)-confirmed cure rate between AP and competing interventions in treating uncomplicated malaria. As for the fever and parasite clearance time, due to the lack of complete data in some studies, only 3 studies' data could be used. The patients showed good tolerance to all drugs, and some side-effects (such as headache, anoxia, vomiting, nausea, and dizziness) were reported for every group, but they were self-limited and showed no significant difference.

Conclusions: AP appeared to show similar efficacy and safety, with a simpler mode of administration and easier compliance when compared with other ACTs used in the treatment of uncomplicated malaria. Considering that the potential evolution of drug resistance is of a great concern, additional RCTs with high-quality and more rigorous design are warranted to substantiate the efficacy and safety in different populations and epidemiological regions.

Keywords: Plasmodium falciparum; artemisinin-piperaquine; efficacy; meta-analysis; safety.

PubMed Disclaimer

Figures

Figure 1
Figure 1
PRISMA flow for data selection.
Figure 2
Figure 2
Comparative drug efficacy between artemisinin–piperaquine and competing interventions.
Figure 3
Figure 3
Comparative fever clearance time (FCT) between ATQ and competing interventions.
Figure 4
Figure 4
Comparative parasite clearance time (PCT) between ATQ and competing interventions.
Figure 5
Figure 5
Comparative drug recurrence rate between artemisinin–piperaquine and competing interventions.
See this image and copyright information in PMC

References

    1. ANZCTR http://www.ANZCTR.org.au.
    1. Baiden R., Oduro A., Halidou T., Gyapong M., Sie A., Macete E., et al. (2015). Prospective observational study to evaluate the clinical safety of the fixed-dose artemisinin-based combination Eurartesim(R) (dihydroartemisinin/piperaquine), in public health facilities in Burkina Faso, Mozambique, Ghana, and Tanzania. Malar. J. 14, 160. 10.1186/s12936-015-0664-9 - DOI - PMC - PubMed
    1. Bassat Q., Mulenga M., Tinto H., Piola P., Borrmann S., Mene´ndezm, et al. (2009). Dihydroartemisinin–piperaquine and artemether– lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial. PloS One 17, e7871. 10.1371/journal.pone.0007871 - DOI - PMC - PubMed
    1. Bruxvoort K. (2014). How patients take malaria treatment: a systematic review of the literature on adherence to antimalarial drugs. PloS One 9 (1), e84555. 10.1371/journal.pone.0084555 - DOI - PMC - PubMed
    1. Davis T. M., Hung T. Y., Sim I. K., Karunajeewa H. A., Ilett K. F. (2005). Piperaquine: aresurgent antimalarial drug. Drugs 65, 75–87. 10.2165/00003495-200565010-00004 - DOI - PubMed

Publication types